The patent for Keytruda, a game-changing immunotherapy medication developed by Merck & Co., is set to expire in 2028. This development potentially allows other pharmaceutical companies to create and market their own versions of the drug. This could increase competition, lower prices, and increase patient access to treatment. However, concerns about availability and quality of generic versions arise. The patent expiration also significantly impacts the pharmaceutical industry and the future of immunotherapy.
How Automation is Advancing Biosimilar Adoption
Many Americans are struggling with the high costs of biologic medications. Although biosimilars, which are cheaper alternatives, exist, they remain underused due to a lack
